Towards efficient data integration and knowledge management in the Agronomic domain

International audienceToday, the revolution in empirical technologies has generated vast amounts of data. This data deluge has created an urgent need to assimilate it with a panoramic view. To this end, information systems play a central role in managing and integrating these data, aiding the biologists in exploiting this integrated information for the extraction of new knowledge. The plant bioinformatics node of the Institut Français de Bioinformatique (IFB) maintains public information systems where a variety of domain specific data are integrated. Currently, efforts are being taken to expose the IFB plant bioinformatics resources as RDF, utilising domain specific ontologies and metadata. Here, we present the overview and the progress of the project

Spectrally reconfigurable quantum emitters enabled by optimized fast modulation

The ability to shape photon emission facilitates strong photon-mediated interactions between disparate physical systems, thereby enabling applications in quantum information processing, simulation and communication. Spectral control in solid state platforms such as color centers, rare earth ions, and quantum dots is particularly attractive for realizing such applications on-chip. Here we propose the use of frequency-modulated optical transitions for spectral engineering of single photon emission. Using a scattering-matrix formalism, we find that a two-level system, when modulated faster than its optical lifetime, can be treated as a single-photon source with a widely reconfigurable photon spectrum that is amenable to standard numerical optimization techniques. To enable the experimental demonstration of this spectral control scheme, we investigate the Stark tuning properties of the silicon vacancy in silicon carbide, a color center with promise for optical quantum information processing technologies. We find that the silicon vacancy possesses excellent spectral stability and tuning characteristics, allowing us to probe its fast modulation regime, observe the theoretically-predicted two-photon correlations, and demonstrate spectral engineering. Our results suggest that frequency modulation is a powerful technique for the generation of new light states with unprecedented control over the spectral and temporal properties of single photons.Comment: 9 pages, 6 figures; Supplementary Informatio

The Galactic Center with Roman

We advocate for a Galactic center (GC) field to be added to the Galactic Bulge Time Domain Survey (GBTDS). The new field would yield high-cadence photometric and astrometric measurements of an unprecedented ${\sim}$3.3 million stars toward the GC. This would enable a wide range of science cases, such as finding star-compact object binaries that may ultimately merge as LISA-detectable gravitational wave sources, constraining the mass function of stars and compact objects in different environments, detecting populations of microlensing and transiting exoplanets, studying stellar flares and variability in young and old stars, and monitoring accretion onto the central supermassive black hole. In addition, high-precision proper motions and parallaxes would open a new window into the large-scale dynamics of stellar populations at the GC, yielding insights into the formation and evolution of galactic nuclei and their co-evolution with the growth of the supermassive black hole. We discuss the possible trade-offs between the notional GBTDS and the addition of a GC field with either an optimal or minimal cadence. Ultimately, the addition of a GC field to the GBTDS would dramatically increase the science return of Roman and provide a legacy dataset to study the mid-plane and innermost regions of our Galaxy.Comment: 19 pages, 3 figures. Submitted to the NASA Roman Core Community Surveys White Paper Cal

The Science Performance of JWST as Characterized in Commissioning

This paper characterizes the actual science performance of the James Webb Space Telescope (JWST), as determined from the six month commissioning period. We summarize the performance of the spacecraft, telescope, science instruments, and ground system, with an emphasis on differences from pre-launch expectations. Commissioning has made clear that JWST is fully capable of achieving the discoveries for which it was built. Moreover, almost across the board, the science performance of JWST is better than expected; in most cases, JWST will go deeper faster than expected. The telescope and instrument suite have demonstrated the sensitivity, stability, image quality, and spectral range that are necessary to transform our understanding of the cosmos through observations spanning from near-earth asteroids to the most distant galaxies.Comment: 5th version as accepted to PASP; 31 pages, 18 figures; https://iopscience.iop.org/article/10.1088/1538-3873/acb29

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Hydrogen storage properties of Mg[BH₄]₂

Among the large variety of possible complex hydrides only few exhibit a large gravimetric hydrogen density and stability around 40 kJ mol⁻¹H₂. Mg[BH₄]₂ is based on theoretical approaches a complex hydride with an equilibrium hydrogen pressure of approximately 1 bar at room temperature and a hydrogen content of 14.9 mass%. The reaction of Li[BH₄] with MgCl₂ at elevated temperatures was investigated as a possible route to synthesize Mg[BH₄]₂. Li[BH₄] reacts with MgCl₂ at a temperature >523 K at a pressure of 10 MPa of hydrogen, where the product contains LiCl and Mg[BH₄]₂. The desorption pc-isotherm of the product obtained at 623 K shows two flat plateaus, which indicates that the decomposition of the product consists of a two-step reaction. The products of the first and the second decomposition reaction were analyzed by means of X-ray diffraction and found to be MgH₂ and Mg, respectively. The enthalpy for the first decomposition reaction was determined to be ΔH = −39.3 kJ mol⁻¹H₂ by the Van’t Hoff plot of the equilibrium measurements between 563 K and 623 K, which is significantly lower than that for pure Li[BH₄] (ΔH = −74.9 kJ mol⁻¹H₂). However, only the second reaction step (MgH₂ → Mg) is reversible at the condition up to 623 K at 10 MPa of hydrogen

Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA - a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749)

BACKGROUND: Median OS after surgery in curative intent for non-metastasized pancreas cancer ranges under study conditions from 17.9 months to 23.6 months. Tumor recurrence occurs locally, at distant sites (liver, peritoneum, lungs), or both. Observational and autopsy series report local recurrence rates of up to 87% even after potentially “curative” R0 resection. To achieve better local control, neoadjuvant CRT has been suggested for preoperative tumour downsizing, to elevate the likelihood of curative, margin-negative R0 resection and to increase the OS rate. However, controlled, randomized trials addressing the impact of neoadjuvant CRT survival do not exist. METHODS/DESIGN: The underlying hypothesis of this randomized, two-armed, open-label, multicenter, phase III trial is that neoadjuvant CRT increases the three-year overall survival by 12% compared to patients undergoing upfront surgery for resectable pancreatic cancer. A rigorous, standardized technique of histopathologically handling Whipple specimens will be applied at all participating centers. Overall, 410 patients (n = 205 in each study arm) will be enrolled in the trial, taking into regard an expected drop out rate of 7% and allocated either to receive neoadjuvant CRT prior to surgery or to undergo surgery alone. Circumferential resection margin status, i.e. R0 and R1 rates, respectively, surgical resectability rate, local and distant disease-free and global survival, and first site of tumor recurrence constitute further essential endpoints of the trial. DISCUSSION: For the first time, the NEOPA study investigates the impact of neoadjuvant CRT on survival of resectable pancreas head cancer in a prospectively randomized manner. The results of the study have the potential to change substantially the treatment regimen of pancreas cancer. TRIAL REGISTRATION: Clinical Trial gov: NCT01900327, DRKS00003893, ISRCTN8219174